Accumulating knowledge suggests that lung tumors overexpress the immunosuppressive protein, PD-L1, and inhibiting this pathway has led to durable benefit in a subset of advanced-stage NSCLC patients (69, 70). The gene discussed is CD274; the disease is non-small cell lung carcinoma.